Status:
RECRUITING
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
University Children's Hospital, Zurich
Centre Hospitalier Universitaire Vaudois
Conditions:
Confirmed Diagnosis of Cystic Fibrosis
Eligibility:
All Genders
Up to 18 years
Brief Summary
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development o...
Detailed Description
Background: Cystic fibrosis (CF) is the most common lethal inherited disease in North European populations, affecting approximately 1:2500 live births. It is a multisystem disorder with respiratory m...
Eligibility Criteria
Inclusion
- Infants with a confirmed diagnosis of CF by NBS
- Age \<=18 years
- Written informed consent by patient and/or parent
Exclusion
- Need for respiratory support for more than three days
- Severe malformations or known diseases other than CF
- Maternal drug abuse
- Known severe maternal disease
- Severe Problems of communication
- Pacemaker, continuous glucose monitor
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2050
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04026360
Start Date
July 1 2011
End Date
December 31 2050
Last Update
November 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital Bern
Bern, Switzerland, 3010